Constellation Pharmaceuticals (Constellation Pharmaceuticals) Debt-to-Equity : 0.01 (As of Mar. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals Debt-to-Equity?

Constellation Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $3.37 Mil. Constellation Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $0.00 Mil. Constellation Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2021 was $377.32 Mil. Constellation Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2021 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Constellation Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

CNST' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.12 Max: 0.86
Current: 0.01

During the past 5 years, the highest Debt-to-Equity Ratio of Constellation Pharmaceuticals was 0.86. The lowest was 0.01. And the median was 0.12.

CNST's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CNST: 0.01

Constellation Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Constellation Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals Debt-to-Equity Chart

Constellation Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Equity

0.61

0.56

0.12

0.01

Constellation Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Debt-to-Equity	Get a 7-Day Free Trial													0.13	0.09	0.09	0.01	0.01

Competitive Comparison of Constellation Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Constellation Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Constellation Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's Debt-to-Equity falls into.

Constellation Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Constellation Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.644	+	0.582)	/	410.724
	=	0.01

Constellation Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.365	+	0)	/	377.319
	=	0.01

Constellation Pharmaceuticals (NAS:CNST) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Constellation Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 First Street, Suite 200, Cambridge, MA, USA, 02142

Website

http://www.constellationpharma.com

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

Executives

Emma Reeve	officer: Chief Financial Officer	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine	officer: See Remarks	C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith	director, 10 percent owner	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey	officer: Chief Medical Officer	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu	director	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia	director	215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha	director, officer: See Remarks	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer	officer: Chief Scientific Officer	215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158